e6vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For
the month of May 2009
Commission File Number 000-28508
Flamel Technologies S.A.
(Translation of registrants name into English)
Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Indicate by check mark whether registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If Yes is marked, indicate below the file number assigned to the registrant in connection
with Rule 12g3-2(b): 82-
INFORMATION FILED WITH THIS REPORT
Document Index
99.1
Press release regarding 2009 first quarter results,
dated May 11, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Flamel Technologies S.A. |
|
|
|
|
|
|
|
|
|
Dated:
May 11, 2009
|
|
By:
|
|
/s/ Stephen H. Willard
|
|
|
|
|
Name:
|
|
Stephen H. Willard
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press release regarding 2009 first quarter results,
dated May 11, 2009.
|
exv99w1
Exhibit 99.1
Flamel Technologies Announces Profitable First Quarter Results;
Increased Cash Levels
LYON, France May 11, 2009 Flamel Technologies (Nasdaq: FLML) today announced its financial
results for the first quarter of 2009. First quarter highlights included:
|
|
Payment by Merck Serono of a 5 million upfront fee following exercise of option to
license Medusa technology for development of an improved formulation of an already marketed
therapeutic protein in Merck Seronos portfolio; |
|
|
|
Achievement and recognition of $4 million milestone from GlaxoSmithKline (GSK), payable in
the second quarter; |
|
|
|
11% growth in revenues; |
|
|
|
Increased cash with no debt; and |
|
|
|
Earnings of $1.2 million. |
For the first quarter 2009, Flamel reported total revenues of $12.1 million versus $10.9 million in
the year-ago period. License and research revenues during the quarter were $7.1 million and
included a $4 million milestone from GSK; license and research revenues during the year-ago quarter
were $3.5 million and included a 500,000 ($0.75 million) milestone from Merck Serono. Product
sales and services, pursuant to the Companys supply contract with GlaxoSmithKline declined in the
first quarter to $2.4 million from $4.7 million in the year-ago quarter. Other revenues in the
quarter were $2.5 million, as compared to $2.6 million in the year-ago quarter.
Operational expenses in the first quarter 2009 declined 22% from $15.8 million in the year-ago
quarter to $12.4 million. Costs of goods and services sold were $2.1 million, as compared to $2.4
million in the first quarter of 2008. Costs and expenses of Flamels research and development were
$7.4 million, compared to $9.3 million in the first quarter of 2008. SG&A expenses during the
quarter declined from $4.1 million in 2008 to $2.9 million in the first quarter 2009.
Net income for the first quarter 2009 was $1.2 million as compared to a net loss of ($3.7) million
in the first quarter of 2008. Net income per share (basic) for the first quarter of 2009 was $0.05,
compared to a net loss per share (basic) in the year-ago period of ($0.15). Net income per share
(diluted) for the first quarter of 2009 was $0.05. Cash and marketable securities at the end of
the first quarter totaled $39.1 million and did not include receipt of the $4 million milestone
from GSK. Cash and marketable securities as of December 31, 2008 were $37.1 million.
Stephen H. Willard, Flamels Chief Executive Officer, stated, During the first quarter, we made
continued progress in expanding our partnership model. We are beginning to enjoy the fruits of
work that we have undertaken over the past few years, such as with the announced license agreement
with Merck Serono. There are numerous additional feasibility studies that could serve as potential
catalysts for further license agreements. The strength of our technology and the success of our
scientists in creating value for our partners are driving this process, which we believe may
accelerate
in the remainder of this year. Our financial strength is an especially important asset
to us as we negotiate these potential license agreements and as we work to develop new feasibility
studies to fuel our future growth.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Micropump® is a
controlled release and taste-masking technology for the oral administration of small molecule
drugs. Flamels Medusa® technology is designed to deliver controlled-release
formulations of therapeutic proteins.
A conference call to discuss earnings is scheduled for 8:30 AM EDT May 11, 2009. To participate in
the conference call, investors in the US and Canada are invited to dial 1-800-860-2442.
International callers are invited to call 1-412-858-4600. The Conference ID number is: 430430. The
webcast of the conference call will be available on the Companys website: www.flamel.com.
Contact:
Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE: + 33 (0) 4 7278-3434
Fax: + 33 (0) 4 7278-3435
Marlio@flamel.com
This document contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including certain plans, expectations, goals and projections
regarding financial results, product developments and technology platforms. All statements that
are not clearly historical in nature are forward-looking, and the words anticipate, assume,
believe, expect, estimate, plan, will, and similar expressions are generally intended to
identify forward-looking statements. All forward-looking statements involve risks, uncertainties
and contingencies, many of which are beyond our control, that could cause actual results to differ
materially from those contemplated in such forward-looking statements. These risks include risks
that products in the development stage may not achieve scientific objectives or milestones or meet
stringent regulatory requirements, uncertainties regarding market acceptance of products in
development, the impact of competitive products and pricing, and the risks associated with Flamels
reliance on outside parties and key strategic alliances. These and other risks are described more
fully in Flamels Annual Report on the Securities and Exchange Commission Form 20-F for the year
ended December 31, 2007. All forward-looking statements included in this release are based on
information available at the time of the release. We undertake no obligation to update or alter
our forward-looking statements as a result of new information, future events or otherwise.
Schedule Attached
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of dollars except share data)
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
2008 |
|
|
2009 |
|
Revenue: |
|
|
|
|
|
|
|
|
License and research revenue |
|
$ |
3,544 |
|
|
$ |
7,089 |
|
Product sales and services |
|
|
4,722 |
|
|
|
2,422 |
|
Other revenues |
|
|
2,599 |
|
|
|
2,543 |
|
|
|
|
|
|
|
|
Total revenue |
|
|
10,865 |
|
|
|
12,054 |
|
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
|
|
|
Cost of goods and services sold |
|
|
(2,409 |
) |
|
|
(2,050 |
) |
Research and development |
|
|
(9,277 |
) |
|
|
(7,385 |
) |
Selling, general and administrative |
|
|
(4,074 |
) |
|
|
(2,946 |
) |
|
|
|
|
|
|
|
Total |
|
|
(15,760 |
) |
|
|
(12,381 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit (loss) from operations |
|
|
(4,895 |
) |
|
|
(327 |
) |
|
|
|
|
|
|
|
|
|
Interest income net |
|
|
381 |
|
|
|
118 |
|
Foreign exchange gain (loss) |
|
|
(113 |
) |
|
|
(74 |
) |
Other income (loss) |
|
|
31 |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
(4,596 |
) |
|
|
(276 |
) |
Income tax benefit (expense) |
|
|
900 |
|
|
|
1,466 |
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
(3,696 |
) |
|
$ |
1,190 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per ordinary share |
|
$ |
(0.15 |
) |
|
$ |
0.05 |
|
Diluted earnings (loss) per share |
|
$ |
(0.15 |
) |
|
$ |
0.05 |
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding (in thousands): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
24,056 |
|
|
|
24,205 |
|
Diluted |
|
|
24,056 |
|
|
|
24,372 |
|